


# LTL-315 datasheet


<b>Origin</b>	Primary human ovarian cancer	<b>Histopathology</b>	High grade serous carcinoma
<b>Year of establishment</b>	2008	<b>Doubling time</b>	13 days
<b>Local invasion</b>	Yes	<b>Metastasis</b>	No
<b>Drug sensitivity</b>	Not determined		

The LTL-315 was developed from a patient's primary ovarian cancer (high grade serous carcinoma). Histopathologically, it closely resembles the patient's tumor (Figs 1, 2). When grafted under the renal capsules of SCID mice, the LTL-315 shows local invasion into adjacent host kidney parenchyma. No metastasis was observed.



**Fig. 1. H&E stained LTL-315 tissue sections.**

LTL-315 tissue grown under the renal capsules of SCID mice, **(A)**. Showing a high grade serous carcinoma. Tumor cells grow in solid sheets with slit-like lumina. (x400) **(B)**. The tumor cells extensively invade into host kidney. (200x)



**Fig. 2. Patient's cancer tissue before grafting.**

The tumor is a high grade serous carcinoma. The tumor cells grow in solid sheets. (400x)

### **Genetic and epigenetic characteristics**

Tissue microarrays containing LTL-315 tissue are available for screening potential molecular targets.

### **Applications**

1. Pre-clinical evaluation of existing and potential anticancer drugs. Examination of drug efficacy on tumor growth, cell death (apoptosis, necrosis), tissue invasion, and angiogenesis.
2. Discovery of potential therapeutic targets and/or biomarkers for drug sensitivity.
3. Study of mechanisms underlying tumor growth and progression.

### **References**

1. Lee et al., Gynecologic Oncology 2005; 96: 48-73
2. Press et al., Gynecologic Oncology 2008; 110: 256-282

For more information, please contact us by email: [LTL@bccrc.ca](mailto:LTL@bccrc.ca) or phone: (604) 675 8013